EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

Author(s):
Smolen, J.S.; Landewe, R.; Breedveld, F.C.; Buch, M.; Burmester, G.; Dougados, M.; Emery, P.; Gaujoux-Viala, C.; Gossec, L.; Nam, J.; Ramiro, S.; Winthrop, K.; Wit, M. de; Aletaha, D.; Betteridge, N.; Bijlsma, J.W.J.; Boers, M.; Buttgereit, F.; Combe, B.; Cutolo, M.; Damjanov, N.; Hazes, J.M.W.; Kouloumas, M.; Kvien, T.K.; Mariette, X.; Pavelka, K.; Riel, P.L.C.M. van; Rubbert-Roth, A.; Scholte-Voshaar, M.; Scott, D.L.; Sokka-Isler, T.; Wong, J.B.; Heijde, D. van der
Published
2014
Publication type
Article / Letter to editor
Rheumatoid ArthritisDMARDs (synthetic)DMARDs (biologic)TreatmentEarly Rheumatoid Arthritis
Date issued
2014-03-31
Language
English
Is part of
Annals of the Rheumatic Diseases (2014), Vol. 73, no. 3, p. 492-509
hdl
1887/101921
doi
10.1136/annrheumdis-2013-204573